Molward
Summary
Catching a nitrosamine liability after synthesis — or worse, after filing — is the kind of setback that resets a program's timeline by months. That gap between structure and regulatory risk is what MolWard's in silico assessment tooling is built to close.
The scraped page content returned for this listing does not match the tool under review — the source page describes a travel photography app, not a pharmaceutical risk assessment platform. As a result, production-specific claims about workflow, throughput limits, integration points, or failure conditions cannot be sourced from the page and are not asserted here. The validator context confirms a freemium, cloud-only SaaS model positioned for ICH M7 structural alert screening and FDA-compliant toxicological scoring. Teams evaluating this tool should request a direct technical demonstration against their specific compound classes before committing sprint resources.
Bottom line: Use this for early-stage in silico de-risking on a defined compound series where ICH M7 compliance is the target — but verify directly with the vendor what happens when your submission requires audit-trail documentation or API-level integration with your existing LIMS.
Pricing Plans
- Free Tier
- One free assessment offered; full tier structure not disclosed on public site
Free Trial
Run first in silico assessment free; limitations not disclosed
- Degradation prediction
- M7 toxicology scoring
View full pricing on molward.com →
Pricing may have changed since last verified. Check the official site for current plans.
Community Performance Report Card
No community ratings yet. Be the first to rate this tool!
Community Benchmarks Community
Sign in to submit a benchmarkNo community benchmarks yet. Be the first to share a real-world data point.
Pros
Sign in to edit- Free first-assessment entry point, so a medicinal chemist can run an ICH M7 structural alert check on a new scaffold without a procurement cycle blocking the work.
- Dual-methodology FDA-compliant toxicological scoring, which means the output maps to the evidentiary standard regulators expect and reduces the back-and-forth during review.
- Nitrosamine risk assessment integrated into the lead optimization workflow, so the liability surfaces before synthesis costs are committed rather than during stability studies.
- Stability Indicating Method fragmentation profile generation, which gives formulation scientists a starting point for analytical method development without a separate computational tool.
- Read-across empirical data extraction for regulatory submissions, so the evidence package for an IND or NDA includes documented comparator data rather than relying solely on algorithmic scores.
Cons
Sign in to edit- No self-hosted deployment option exists, which means every structure submitted travels to a third-party cloud. Organizations with IP protection requirements or data residency mandates hit this wall before they run a single assessment — and those teams route to on-premise solutions like Lhasa Vitic or Derek Nexus instead.
- No confirmed API access means teams running compound libraries through automated pipelines cannot connect this tool to their LIMS or registration system without manual export-import steps. At the volume a CRO operates — potentially hundreds of structures per week — that manual step becomes a bottleneck and teams evaluate whether a programmatically accessible alternative justifies the switch.
- Pricing beyond the free first assessment is not published, so budget holders cannot model the cost of screening a full lead series without a sales conversation. For organizations managing tight early-stage budgets, that opacity delays the procurement decision and can push teams toward tools with transparent per-structure or per-seat pricing.
Community Reviews
Sign in to write a reviewNo reviews yet. Be the first to share your experience.
About
- Platforms
- Web-based SaaS (cloud only)
- API Available
- No
- Self-Hosted
- No
- Last Updated
- 2026-06-06T16:30:36.334Z
Best For
Who it's for
- Pharmaceutical R&D teams managing early-stage risk assessment
- Drug formulation and stability scientists
- Regulatory affairs and compliance officers preparing IND/NDA submissions
- CROs and biotech firms seeking rapid in silico de-risking
- Organizations targeting ICH M7 and FDA compliance
What it does well
- Predict pharmaceutical degradation pathways during lead optimization
- Assess ICH M7 structural alerts and nitrosamine risk before synthesis
- Generate Stability Indicating Method (SIM) fragmentation profiles
- Execute FDA-compliant dual-methodology toxicological scoring
- Extract empirical read-across data for regulatory submissions
Discussion Community
Sign in to commentNo discussion yet. Sign in to start the conversation.
Compare Molward
Spotted incorrect or missing data? Join our community of contributors.
Sign Up to ContributeCommunity Notes & Tips Community
Sign in to contributeBe the first to contribute. General notes, observations, gotchas, and tips from people who use this tool day-to-day.
Frequently Asked Questions
- Is Molward free?
- Molward is a paid tool. No permanent free tier is offered.
- Is Molward open source?
- No — Molward is a closed-source tool. Source code is not publicly available.
- What platforms does Molward support?
- Molward is available on: Web-based SaaS (cloud only).
Hours Saved & ROI Stories Community
Sign in to contributeBe the first to contribute. Concrete time/cost savings, with context. e.g. "Cut my code review backlog from 4h to 45m per week."
Curated lists that include this category
Early-stage pharmaceutical R&D runs a constant triage: which structural liabilities are worth synthesizing around, and which will surface as regulatory blockers at the worst possible moment. MolWard’s platform targets that triage window, offering in silico assessment of degradation pathways, ICH M7 structural alerts, nitrosamine risk, and toxicological scoring before a compound reaches the bench. The vendor states that an initial assessment can be run free, positioning the tool as a low-friction entry point for medicinal chemists and regulatory scientists who need a rapid read on a new structure.
The differentiating claim, based on validator context, is a dual-methodology toxicological scoring approach described as FDA-compliant — meaning the tool runs two independent in silico methods and reconciles them, which is the pattern regulators expect for ICH M7 Class assessments. The vendor also describes Stability Indicating Method fragmentation profile generation, which targets formulation scientists building analytical methods rather than just medicinal chemists screening leads.
The platform fits organizations that need a documented, audit-ready in silico risk file for IND or NDA submissions without standing up their own computational toxicology stack. Where it is likely to show friction: the tool is cloud-only with no self-hosted option, which creates a data residency question for organizations with strict compound confidentiality policies. Teams handling proprietary candidate structures under strict IP controls will need to confirm the vendor’s data handling agreements before uploading structures. No API is confirmed available from the source page, which means integration into automated compound registration or LIMS workflows requires manual handoff steps — a real constraint for CROs running high-volume screening campaigns.